A machine learning-derived intratumoral heterogeneity-related signature predicts the prognosis for and therapeutic response in patients with skin cutaneous melanoma
Jul 2026· Translational Cancer Research· Vol 15, pp. 604-604· 0 citations· 24 references
Medicine
TL;DR
The machine learning-derived PIRS robustly predicts prognosis in SKCM patients and is promising for optimizing patient risk stratification and treatment decisions, though further prospective validation is warranted.
Abstract
Background Reliable biomarkers for predicting prognosis and therapeutic response in skin cutaneous melanoma (SKCM) remain limited. This study aimed to develop an intratumoral heterogeneity (ITH)-related prognostic signature for SKCM using integrative machine learning. Methods RNA sequencing (RNA-seq) data from 472 SKCM patients in The Cancer Genome Atlas (TCGA) and 214 patients in the GSE65904 cohort were analyzed. ITH scores were calculated using the DEPTH2 algorithm. Differentially expressed genes (DEGs) were identified between high- and low-ITH groups [|log2fold change (FC)| ≥1, false discovery rate (FDR) <0.05]. Based on 38 prognostic DEGs identified by univariate Cox regression, we employed an integrative framework of 101 machine learning algorithm combinations to construct prognostic models in the TCGA training cohort. The model with the highest average concordance index (C-index) was validated in the GSE65904 cohort and selected as the prognostic ITH-related signature (PIRS). Associations of the PIRS risk score with tumor mutational burden (TMB), immune cell infiltration, immune checkpoint gene expression, and drug sensitivity were systematically evaluated. Model performance was assessed using receiver operating characteristic (ROC) curves and Cox regression analyses. Results A 38-gene PIRS was constructed using the plsRcox algorithm. Patients with high PIRS risk scores exhibited significantly poorer overall survival (OS) in both the TCGA and Gene Expression Omnibus (GEO) cohorts. The PIRS was identified as an independent prognostic factor, with area under the curve (AUC) values of 0.779, 0.734, and 0.756 for 1-, 3-, and 5-year survival, respectively. High-risk samples displayed significantly lower TMB (P<0.05), reduced immune and stromal cell infiltration (P<0.001), downregulated immune function, and decreased expression of immune checkpoint genes. Additionally, high- and low-PIRS risk score groups exhibited distinct sensitivity patterns to different classes of targeted agents. Conclusions The machine learning-derived PIRS robustly predicts prognosis in SKCM patients. Its clinical application is promising for optimizing patient risk stratification and treatment decisions, though further prospective validation is warranted.
Skin cutaneous melanoma (SKCM) is the third most common cause of cancer-related deaths globally. Today, precise biomarkers to predict melanoma prognosis are quite limited. Aerobic glycolysis serves as the primary metabolic pathway for malignancies to meet their rapid growth demands. This study built a glycolysis-associ...
Chen-Shan Jiang, Sen Niu, Chen Li et al.· Melanoma research· 0 citations
A three-gene signature provides a new exploratory prognostic model while inferring a COMP+ to NELL2+ transcriptional transition and demonstrates the value of AI-driven multi-omics integration for precision oncology.
Xue-Qian Zhang, Wei Zhang, Zheng Wang et al.· Genes· 0 citations
EZH2, CDK1, and AURKA constitute an internally validated prognostic risk signature in PCa that links cell cycle dysregulation to an immunosuppressive tumor microenvironment and provides clinically actionable risk stratification and highlights candidate therapeutic targets in prostate cancer.
Gu-Quan Chen, Jie-Feng Zhang, Lin-Fu Zhao et al.· Frontiers in Genetics· 0 citations
This single-cell landscape of chemoresistance-associated proliferation genes delineates a nine-gene prognostic signature for HGSOC and confirms hub-gene overexpression in cisplatin-resistant cells, nominating therapeutic targets.
Yan-Min Zhang, Si-Huang Wu, Hui-Zhu Lin et al.· Translational Oncology· 0 citations
The RSF model provides accurate, robust, and interpretable prognostication for N1M0 prostate cancer, and enables precise risk stratification and individualized treatment planning as a web-based calculator.
Er-Hao Bao, Y. Chai, Yang Yang et al.· The Aging Male· 0 citations
This study is the first to comprehensively integrate clinical, pathological, serological, and demographic factors into CRC prognostic nomograms, which outperform traditional staging and enable more personalized, clinically actionable prognosis prediction for CRC patients.
Hai-Lun Xie, Li-Shuang Wei, Tai-Zhong Chen et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.